BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Novartis
Genentech
Amgen
Information provided by (Responsible Party):
Herbert Hurwitz, Duke University Medical Center
ClinicalTrials.gov Identifier:
NCT00586443
First received: December 21, 2007
Last updated: April 4, 2013
Last verified: April 2013
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: November 2013
  Estimated Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)